4.7 Article

Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Oncology

Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent

Bruna Pellini et al.

Summary: Circulating tumor DNA minimal residual disease is a powerful biomarker with the potential to improve survival outcomes for non-small-cell lung cancer. Although the current studies are limited in size, largely retrospective, and without thorough prospective clinical validation, the detection of ctDNA minimal residual disease has shown good sensitivity and specificity at the first post-treatment timepoint, and improved performance in surveillance.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Review Oncology

Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease

Everett J. Moding et al.

Summary: ctDNA MRD predicts relapse after treatment for solid tumors, potentially revolutionizing personalized adjuvant therapies. However, results can be influenced by factors such as assay type, amount of ctDNA release, and technical background, requiring cautious consideration.

CANCER DISCOVERY (2021)

Article Oncology

TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer

Hongling Liang et al.

Summary: Immune characteristics, TMB, TCR, and TILs were simultaneously analyzed in breast cancer patients receiving neoadjuvant chemotherapy. Higher TMB and TCR diversity index were found in non-pCR patients compared to pCR patients, with a linear correlation between TMB and TCR. High TCR clonality and CD8+ expression were associated with disease-free survival, suggesting potential for guiding neo-adjuvant treatment in operable breast cancers.

FRONTIERS IN ONCOLOGY (2021)

Article Medicine, General & Internal

Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study

Pradeep S. Chauhan et al.

Summary: The study aimed to develop a noninvasive liquid biopsy method for urine DNA analysis to assist in selecting patients suitable for bladder-sparing treatment.

PLOS MEDICINE (2021)

Article Medicine, General & Internal

Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study

Jeffrey J. Szymanski et al.

Summary: This study utilized fragment size analysis and ultra-low-pass whole genome sequencing of plasma cell-free DNA to distinguish between MPNST and PN in NF1 patients. A noninvasive classifier was developed with 86% pretreatment accuracy and 89% accuracy on serial analysis to differentiate MPNST from PN.

PLOS MEDICINE (2021)

Article Oncology

Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA

Jonathan C. Dudley et al.

CANCER DISCOVERY (2019)

Correction Biochemistry & Molecular Biology

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer (vol 171, pg 540, 2017)

A. Gordon Robertson et al.

Article Multidisciplinary Sciences

Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors

Viktor A. Adalsteinsson et al.

NATURE COMMUNICATIONS (2017)

Article Biotechnology & Applied Microbiology

Integrated digital error suppression for improved detection of circulating tumor DNA

Aaron M. Newman et al.

NATURE BIOTECHNOLOGY (2016)

Article Multidisciplinary Sciences

Comprehensive molecular characterization of urothelial bladder carcinoma

John N. Weinstein et al.

NATURE (2014)

Article Biochemistry & Molecular Biology

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

Aaron M. Newman et al.

NATURE MEDICINE (2014)